OncoMethylome's Partner Veridex Licenses Prostate Cancer Methylation Technology to Laboratory Corporation of America Holdings


OncoMethylome Sciences announced that its commercial partner Veridex, LLC, granted a license to Laboratory Corporation of America® Holdings (LabCorp®) which permits LabCorp to commercialize nucleic acid testing technology for detecting the presence of a key tissue marker in prostate cancer, methylated GST-Pi.

The prostate cancer marker and methylation technology required to detect it were initially developed by OncoMethylome Sciences and were licensed to Veridex in a commercial deal that was announced on January 19, 2005. LabCorp is the first fullservice, national clinical laboratory in the U.S. to access this new technology. Terms of the agreement were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances